XPENG-MOTORS
27.4.2020 13:48:11 CEST | Business Wire | Press release
Xpeng Motors, a leading Chinese electric vehicle and technology company, today announced the launch of its P7 super-long range, high-performance, fast-charging intelligent EV sports sedan, its second production model. The P7 is immediately available for order in China, in 3 versions and 8 configurations, and customer deliveries will commence end June 2020, starting at RMB 229,900 – 349,900 (US$32,462 – 49,404) post subsidies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200427005378/en/
“Today is a milestone in the 5-year history of Xpeng Motors,” said He Xiaopeng, Chairman & CEO. “The P7’s launch solidifies Xpeng Motors’ leading position in China’s smart EV market. Our ability to launch the P7 in the challenging conditions of the COVID-19 crisis is a testament to the strength of our young company.”
With superior autonomy and connectivity, the Xpeng P7 incorporates many breakthroughs and firsts. It is the first L3 autonomy-ready production vehicle in the Chinese market. It boasts world-beating NEDC 706km super-long driving range and 4.3s 1-100km/h acceleration in some configurations. It is the first production model in any market worldwide powered by NVIDIA’s DRIVE AGX Xavier system-on-a-chip, delivering 30 TOPS (trillions of operations per second) performance while consuming only 30 watts of power.
Strong performance against key industry benchmarks
- High-performance 3-in-1 electric drive system – compact, light, efficient, reliable – with world-class motor energy density of 2.0 kW/kg and an efficiency up to 97.5%.
- Longest-driving range EV in China at NEDC 706km.
- World’s first EV with Infineon 950 IGBT module, delivering up to 580A to motor for continuous 40s.
- German luxury sports style auto brand joint-developed chassis, optimized suspension & layout.
- Bosch / Brembo braking system, new-gen Bosch iBooster braking recycling, c.100% energy recovery, with 35m 100km/h brake distance.
- Autonomous driving system XPILOT3.0 for China’s challenging roads - 12 ultrasonic sensors, 5 millimeter-wave radars, 14 cameras – industry’s only 360° multi-perception integrated system.
- Qualcomm Snapdragon 820 high-performance auto chip running Xpeng Xmart OS 2.0 - world’s first intelligent full-scenario voice interactive system, integrating App stores and Alipay mini-program dual ecosystem.
- Whole-car OTA upgrade capability for in-car apps as well as ECU-controlled functions, supported by its SEPA (Smart Electric Platform Architecture).
- CATL high-density slim-profile prismatic battery pack, 110mm height, 80.9kWh with energy density reaching 170Wh/kg.
- Fast charging: from 30% to 80% charge as fast as 28 mins, 120km range in 10 mins; with China’s first remote-controlled concealed charging plug.
- 5-level safety design: Passive, battery, active, air quality and data security measures.
Market-leading autonomous driving architecture
The Xpeng P7 has the strongest autonomous driving architecture among production vehicles in China. Powered by NVIDIA's DRIVE Xavier, the P7 operates both the XPILOT3.0 and XPILOT2.0 systems concurrently to provide complete redundancy. The XPILOT3.0 reaches high levels of Functional Safety to offer guaranteed stability and security. As the foundation of the Xpeng P7s technology, the safety framework is designed and benchmarked to C-NCAP 5-star standards.
The P7’s multiple front-facing, side and rear-facing cameras cover a 180°-degree+ field of view, following tight curves and recognizing vehicles cutting in at close quarters. The P7 is equipped with the industry’s first new-generation forward-looking millimeter wave radar sensors, with detection distance over 200 meters, offering market-leading accuracy and angle of view, effectively penetrating rain, fog, haze to perceive surroundings in reduced visibility conditions. Four more high-performance millimeter wave radars are positioned at each corner of the P7 – an industry-leading configuration.
The P7’s lane-level positioning function is backed by AutoNavi’s high-definition high-precision maps with high-level accuracy. The GPS/RTK/IMU positioning hardware allows positioning accuracy to the centimeter level, or less than 0.3% thanks to real-time positioning map construction technology (SLAM). These complementary features effectively enhance the stability and safety of the P7’s autonomous driving function on overpasses, in tunnels or under bad weather conditions. Coupled with the precise control capabilities brought by Bosch iBooster, the P7 performs a suite of advanced ADAS functions, including navigation-guided pilot (NGP) for highways, traffic light recognition assistance and the first production model to feature memory parking for car parks.
Superior style and support
As well as high technology, the P7 boasts superior styling and ergonomic features designed to enrich and enhance the driving experience. The bodywork is crafted with an elegant minimalist profile that lowers air resistance to a market-leading Cd0.236, delivering longer range and a quieter, smoother ride.
The intelligent cockpit is designed to interact with driver and passengers through voice commands, infotainment, and a concert hall-standard 600w Dynaudio surround-sound audio environment. A panoramic glass roof, frameless doors, and a low-profile console offer wide-angle views in all directions. Nappa leather styling is available for that extra touch of luxury.
The P7 will be available through Xpeng’s growing sales network, already some 113 outlets across 57 cities, and its service network of 73 stores in 52 cities. Supercharging stations for the P7 have already reached 164 contracted and signed units across 35 cities, while its supporting 3rd-party charging pile networks number some 200,000+ units across China.
“Our philosophy of end-to-end closed-loop R&D is what sets us apart among China’s intelligent EV manufacturers,” Chairman He concluded. “Regular OTA upgrades will ensure that the P7 continues to grow and improve as we do.”
The Xpeng P7 is immediately available in China in various configurations, starting from RMB 229,900 – 349,900 (US$32,462 – 49,404) post subsidies.
4WD High Performance (4.3s 0-100km/h acceleration): RMB 339,900 – 349,900
RWD Super-Long Range: (656km – 706km NEDC): RMB 254,900 – 276,900
RWD Long Range (568km NEDC) RMB 229,900 – 259,900
(All post subsidies)
For Xpeng P7’s videos and images please visit : https://183.236.41.237
Log-in name: xpfilelv2
Password: xpfile@P7@
About XPENG Motors
Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/
Follow us on social media for latest Xpeng news:
Facebook
Twitter
LinkedIn
YouTube
Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20200427005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
